# Submission Package Quality Check Report

**Date**: January 28, 2026  
**Journal**: Antibody Therapeutics (Oxford University Press)  
**Manuscript**: CDR3 length dictates the humanization limit of VHH framework region 2

---

## Checklist

### Manuscript Quality
- [x] AI traces removed (no emojis, placeholders, or AI-typical phrases)
- [x] Journal format applied (Abstract sections, Highlights, Statement of Significance)
- [x] Chapter numbering corrected (1. Introduction / 2. Methods / 3. Results / 4. Discussion)
- [x] References reformatted to journal style (no annotations)
- [x] Authors added (Jing Huang, Linqi Zhang)
- [x] Ethics statements added

### Data Integrity
- [x] CDR3 threshold unified to 11 aa throughout
- [x] Key position corrected from "IMGT 47" to "IMGT 50"
- [x] Sample sizes verified: Short ≤11 (N=5), Long >11 (N=14)
- [x] Class statistics verified:
  - Class 1: N=5, Mean CDR3=9.0, Human ID=93.2%
  - Class 2: N=10, Mean CDR3=17.6, Human ID=87.9%
  - Class 3: N=4, Mean CDR3=15.2, Human ID=87.2%
- [x] P-values confirmed: P=0.00175, ρ=-0.604, P=0.77
- [x] IMGT 50 frequency: Arg in 13/14 long-CDR3 VHHs (93%)

### Files
- [x] Manuscript: `Manuscript_VHH_Humanization.md` (ready)
- [x] Table 1: `Tables/Table1_Clinical_Landscape.csv` (19 rows verified)
- [x] Table S1: `Tables/TableS1_Residue_Frequencies.csv` (11 positions)
- [x] Figures: 10 PNG files confirmed present
  - Figure 1A, 1B (phylogenetic trees)
  - Figure 2A-H (sequence logos)
- [x] Supplementary materials: organized in `../Supplementary_Materials/`

### References
- [x] 12 references reformatted to journal style
- [x] Key references verified:
  - [1] Hamers-Casterman 1993 Nature - confirmed
  - [4] North & Dunbrack 2011 JMB - confirmed
  - [8] Scully 2019 NEJM (Caplacizumab) - confirmed
  - [12] Schoof 2020 Science (SARS-CoV-2 nanobody) - confirmed

### Removed Items
- [x] Cover letter deleted (per user request)
- [x] All AI-typical markers removed
- [x] Internal workflow notes removed
- [x] Time estimates removed
- [x] Emoji and symbols removed

---

## Outstanding Items (Before Submission)

1. Convert `Manuscript_VHH_Humanization.md` to DOCX/PDF
2. Format `Table1_Clinical_Landscape.csv` as Word/Excel table
3. Format `TableS1_Residue_Frequencies.csv` as Word/Excel table
4. Combine Figure 2 panels (A-H) into single multi-panel figure (optional)
5. Zip supplementary materials
6. Add corresponding author email/ORCID if required by journal

---

## Quality Assurance

### Language
- Objective, measured scientific tone
- No hyperbolic claims or AI-typical phrases
- Direct statements without excessive modifiers
- Natural sentence structure variation

### Data
- All statistics traceable to source files in `Supplementary_Materials/Analysis_Reports/`
- Cross-referenced with ANARCI numbering CSV
- Consistent use of CDR3 threshold = 11 aa
- IMGT position 50 (not 47) as key FR2 site

### Format
- Follows Antibody Therapeutics structure (based on OUP articles)
- Includes required sections: Highlights, Statement of Significance
- Ethics and funding statements included
- Figure legends separated from main text
- References in journal format (no DOIs in main citations)

---

## Files Ready for Submission

### Primary Files
1. `Manuscript_VHH_Humanization.md` - Main manuscript
2. `Tables/Table1_Clinical_Landscape.csv` - Table 1
3. `Tables/TableS1_Residue_Frequencies.csv` - Table S1
4. `Figures/*.png` (10 files) - All figures

### Supporting Documentation
- `SUPPLEMENTARY_MATERIALS_LIST.md` - Complete inventory
- `README_SUBMISSION.md` - Package overview
- `SUBMISSION_READY_REPORT.md` - This file

---

**Status**: Ready for format conversion and submission

**Recommendation**: After converting to DOCX/PDF, do a final manual proofread for:
- Typographical errors
- Figure/table callouts
- Reference numbering
- Author affiliations format
